Varenicline treatment for methamphetamine dependence: A randomized, double-blind Phase II clinical trial

Methamphetamine (MA) dependence is a significant source of deleterious consequences to individual and public health (Cruickshank and Dyer, 2009). Approximately 469,000 people aged 12 and older in the U.S. meet the DSM-IV criteria for MA dependence, and the economic burden of MA use in the U.S. is approximately $23.4 billion per year (Nicosia et al., 2009; Substance Abuse and Mental Health Services Administration, 2014). Available behavioral treatments, including cognitive behavioral therapy (CBT) and contingency management (CM), are only modestly effective (Lee and Rawson, 2008; Roll, 2007).

Source: Drug and Alcohol Dependence - May 25, 2018 Category: Addiction Authors: Marisa Briones, Steven Shoptaw, Ryan Cook, Matthew Worley, Aimee-Noelle Swanson, David E. Moody, Wenfang B. Fang, John Tsuang, Benjamin Furst, Keith Heinzerling Tags: Full length article Source Type: research